• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GALDERMA Q-MED RESTYLANE LYFT WITH LIDOCAINE; IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GALDERMA Q-MED RESTYLANE LYFT WITH LIDOCAINE; IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Abscess (1690); Foreign Body Reaction (1868); Unspecified Infection (1930); No Code Available (3191)
Event Date 04/24/2019
Event Type  Injury  
Manufacturer Narrative
Manufacturer narrative: lot number was not reported.Pharmacovigilance comment: the serious event of abscess and the non-serious events of implant site pustule and foreign body reaction were considered expected and possibly related to the treatment.Serious criteria include the need for medical intervention to prevent permanent damage including incision and drainage of the abscess.The non-serious event of possible cryptococcal cutaneous infection was considered unexpected and possibly related to the treatment.Potential etiologies for the reported events include microbial contamination and opportunistic infection.Potential contributory factors include inadequate aseptic, injection or post treatment techniques, immunodeficiency secondary to etanercept therapy and medical history, and inflammatory reaction secondary to the infection.The case meets the seriousness criteria for expedited reporting to the regulatory authorities.Capa comment: the information in this single case does not suggest involvement of a nonconforming product or quality problem and will not initiate a corrective or preventive action.
 
Event Description
Case reference number (b)(4) is a spontaneous report sent on (b)(6) 2019 by a physician which refers to a (b)(6) year-old caucasian female patient.The patient medical history included psoriasis, hypothyroidism.The patient had had left parotidectomy in the past.The patient had no known allergies.Concomitant treatments included etanercept [etanercept], synthroid [synthroid], sertraline [sertraline] and omeprazole [omeprazole].The patient had previously received treatment with unspecified fillers in the past.On (b)(6) 2019, the patient received treatment with 3 ml restylane lyft with lidocaine with 29 gauge needle (unknown lot number and injection technique) into left cheek for the indication of defect/concavity from parotid surgery) and in the left lateral mid face.23 days later, on (b)(6) 2019, the patient experienced pustule on the left cheek (implant site pustules).It was reported that 5 ml was drained and cultured which did not show any growth.27 days later, on (b)(6) 2019, the patient experienced enormous abcess on the left cheek (implant site abscess).20 ml of pus was drained, cultured and also sent to a medical center for pathological examination which suggested multiple histiocytes foreign body reaction (foreign body reaction) and questionable cryptococcus liquifaciens (cryptococcal cutaneous infection).The patient was treated with incision and drainage through skin and packing.The patient was improving.The reporter assessed the case as serious due to the intervention with i&d of the abscess.Outcome at the time of the report: pustule left cheek was recovering/resolving.Abcess left cheek was recovering/resolving.Suggests multiple histiocytes foreign body reaction was recovering/resolving.Questionable cryptococcus liquifaciens was recovering/resolving.Tracking list: v.0 initial, v.1 fu received on 14-jun-2019.Suspect device details including volume, implant date, site and needle type was updated.Case upgraded to serious based on the information received on 14-jun-2019.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESTYLANE LYFT WITH LIDOCAINE
Type of Device
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
GALDERMA Q-MED
seminariegatan 21
uppsala, SE-75 2 28
SW  SE-752 28
Manufacturer (Section G)
GALDERMA Q-MED
seminariegatan 21
uppsala, SE-75 2 28
SW   SE-752 28
Manufacturer Contact
amy poteate
14501 north freeway
fort worth, TX 76177
8175615353
MDR Report Key8780596
MDR Text Key150831734
Report Number9710154-2019-00070
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P040024/S073
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Physician
Type of Report Initial
Report Date 07/11/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/11/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/14/2019
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age66 YR
-
-